[1] Vandooren J, Van den Steen PE, Opdenskker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase9(MMP9): the next decade[J]. Crit Rev Biochem Mol Biol, 2013, 48(3): 222272. DOI: 10.3109/10409238.2013.770819.
[2] Horng CT, Yang JS, Chiang JH, et al. Inhibitory effects of tetrandrine on epidermal growth factorinduced invasion and migration in HT29 human colorectal adenocarcinoma cells[J]. Mol Med Rep, 2015, 13(1): 10031009. DOI: 10.3892/mmr.2015.4635.
[3] Romero D, AlShareef Z, GorrooEtxebarria I, et al. Dickkopf3 regulates prostate epithelial cell acinar morphogenesis and prostate cancer cell invasion by limiting TGFβdependent activation of matrix metalloproteases[J]. Carcinogenesis, 2016, 37(1): 1829. DOI: 10.1093/carcin/bgv153.
[4] Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinase are essential for the inflammatory response in cancer cells[J]. J Signal Transduct, 2010, 2010: 985132. DOI: 10.1155/2010/985132.
[5] Hurst NG, Stocken DD, Wilson S, et al. Elevated serum matrix metalloproteinase 9 (MMP9) concentration predicts the presence of colorectal neoplasia in symptomatic patients[J]. Br J Cancer, 2007, 97(7): 971977. DOI: 10.1038/sj.bjc.6603958.
[6] Wilson S, Damery S, Stocken DD, et al. Serum matrix metalloproteinase 9 and colorectal neoplasia: a communitybased evaluation of a potential diagnostic test[J]. Br J Cancer, 2012, 106(8): 14311438. DOI: 10.1038/bjc.2012.93.
[7] GimenoGarcía AZ , Trianes J, Quintero E, et al. Plasma matrix metalloproteinase 9 as an early surrogate biomarker of advanced coloerctal neoplasia[J]. Gastroenterol Hepatol, 2015, In press. DOI: 10.1016/j.gastrohep.2015.10.002.
[8] Jensen SA, Vainer B, Bartels A, et al. Expression of matrix metalloproteinase9 (MMP9) and tissue inhibitor of metalloproteinases 1 (TIMP1) by colorectal cancer cells and adjacent stroma cellsassociations with histopathology and patients outcome[J]. Eur J Cancer, 2010, 46(18): 32333242. DOI: 10.1016/j.ejca.2010.07.046.
[9] Bendardaf R, Buhmeida A, Hilska M, et al. MMP9 (gelatinase B) expression is associated with diseasefree survival and diseasespecific survival in colorectal cancer patients[J]. Cancer Invest, 2010, 28(1): 3843. DOI: 10.3109/07357900802672761.
[10] Buhmeida A, Bendardaf R, Hilska M, et al. Prognostic significance of matrix metalloproteinase9 (MMP9) in stage Ⅱ colorectal carcinoma[J]. J Gastrointest Cancer, 2009, 40(34): 9197. DOI: 10.1007/s120290099091x.
[11] Langers AM, Verspaget HW, Hawinkels LJ, et al. MMP2 and MMP9 in normal mucosa are independently associated with outcome of colorectal cancer patients[J]. Br J Cancer, 2012, 106(9): 14951498. DOI: 10.1038/bjc.2012.80.
[12] Chu D, Zhao Z, Zhou Y, et al. Matrix metalloproteinase9 is associated with relapse and prognosis of patients with colorectal cancer[J]. Ann Surg Oncol, 2012, 19(1): 318325. DOI: 10.1245/s1043401116863.
[13] Zheng CG, Chen R, Xie JB, et al. Immunohistochemical expression of Notch1, Jagged1, NFκB and MMP9 in colorectal cancer patients and the relationship to clinicopathological parameters[J]. Cancer Biomark, 2015, 15(6): 889897. DOI: 10.3233/CBM150533.
[14] Araújo RF Jr, Lira GA, Vilaa JA, et al Prognostic and diagnostic implications of MMP2, MMP9, and VEGFα expressions in colorectal cancer[J]. Pathol Res Pract, 2015, 211(1): 7177. DOI: 10.1016/j.prp.2014.09.007.
[15] Hawinkels LJ, Kuiper P, Wiercinska E, et al. Matrix metalloproteinase14 (MT1MMP)mediated endoglin shedding inhibits tumor angiogenesis[J]. Cancer Res, 2010, 70(10): 41414150. DOI: 10.1158/00085472.CAN094466.
[16] Li X, Wu JF. Recent developments in patent anticancer agents targeting the matrix metalloproteinases (MMPs)[J]. Recent Pat Anticancer Drug Discov, 2010, 5(2): 109141. DOI: 10.2174/157489210790936234. |